British pharmaceutical company GlaxoSmithKline (GSK) is investing £ 130 million, or € 142 million, for a 10 percent stake in German biotechnologist CureVac, who is developing a vaccine against the SARS v2 virus. The parties will cooperate in the field of vaccines.
With the investment in CureVac tries to get a lead in lucrative vaccine business. The only catch is that the COVID-19 vaccine may simply not exist. Out of seven known human coronoviruses exactly zero have a working vaccines for it. Immunity seems to be very short-term.
Furthermore, CureVac will also receive other payments from GSK. The collaboration concerns vaccines based on so-called mRNA technology. CureVac’s experimental vaccines against coronavirus and rabies are not included in the transaction. In June it was announced that the German government had taken a 23 percent stake in CureVac for 300 million euros. Donald Trump has searched ways to purchase CureVac. Perhaps he found less direct approaches more effective.
